Global Bladder Cancer Therapeutics Market 2017-2021

  • ID: 4298768
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 6

FEATURED COMPANIES

  • Accord Healthcare
  • AstraZeneca
  • Bedford Lab
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffman-La Roche
  • MORE
About Bladder Cancer Therapeutics

The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.

The analysts forecast the global bladder cancer therapeutics market to grow at a CAGR of 4.77% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global bladder cancer therapeutics market for 2017-2021. To calculate the market size, the report considers the sales from both branded and generic drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Bladder Cancer Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Bristol-Myers Squibb
- Eli Lilly
- F. Hoffman-La Roche
- Pfizer

Other prominent vendors
- Accord Healthcare
- AstraZeneca
- Bedford Lab
- Merck
- Sanofi

Market drivers
- Growing prevalence rate leads to higher prescription value
- For a full, detailed list, view the full report

Market challenges
- Economic burden of bladder cancer
- For a full, detailed list, view the full report

Market trends
- Advent of novel pipeline
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Accord Healthcare
  • AstraZeneca
  • Bedford Lab
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffman-La Roche
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
  • Bladder
  • Bladder cancer
  • Currently approved therapeutic regimen
  • Stages of bladder cancer
PART 05: Key clinical trials

PART 06: Market landscape
  • Market size and forecast
  • Five forces analysis
PART 07: Market segmentation by therapy
  • Intravesical therapy
  • Chemotherapy
  • Preservation therapy
  • Others
PART 08: Geographical segmentation
  • Bladder cancer therapeutics market in Americas
  • Bladder cancer therapeutics market in EMEA
  • Bladder cancer therapeutics market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Growing influence of targeted biologics
  • Advent of novel pipeline
  • Emergence of effective diagnostic tools
PART 12: Vendor landscape
  • Competitive landscape
PART 13: Key vendor analysis
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffman-La Roche
  • Pfizer
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Approved therapeutics for the treatment of bladder cancer
Exhibit 02: Stages of bladder cancer
Exhibit 03: Pipeline landscape based on development phase 2016
Exhibit 04: Key clinical trials
Exhibit 05: Snapshot of therapy-based pipeline in global bladder cancer market
Exhibit 06: Market scenario for global bladder cancer therapeutics market 2016-2021 ($ million)
Exhibit 07: Global bladder cancer therapeutics market revenue 2016-2021 ($ millions)
Exhibit 08: Opportunity analysis of global bladder cancer therapeutics market
Exhibit 09: Five forces analysis
Exhibit 10: Segmentation of global bladder cancer therapeutics market by therapy 2016
Exhibit 11: Global bladder cancer therapeutics market segmentation based on therapy 2016 (%)
Exhibit 12: Global bladder cancer therapeutics market for intravesical therapy 2016-2021 ($ millions)
Exhibit 13: Global bladder cancer therapeutics market for chemotherapy 2016-2021 ($ millions)
Exhibit 14: Global bladder cancer therapeutics market for preservation therapy 2016-2021 ($ millions)
Exhibit 15: Segmentation of global bladder cancer therapeutics market based on geography 2016 and 2021
Exhibit 16: Global bladder cancer therapeutics market revenue by geography 2016-2021 ($ millions)
Exhibit 17: Global bladder cancer therapeutics market share by geography 2016-2021 (%)
Exhibit 18: Market scenario in Americas
Exhibit 19: Bladder cancer therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: Bladder cancer therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 22: Market scenario in APAC
Exhibit 23: Bladder cancer therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 24: Competitive structure analysis of global bladder cancer therapeutics market 2016
Exhibit 25: Bristol-Myers Squibb: Key highlights
Exhibit 26: Bristol-Myers Squibb: Strength assessment
Exhibit 27: Bristol-Myers Squibb: Strategy assessment
Exhibit 28: Bristol-Myers Squibb: Opportunity assessment
Exhibit 29: Eli Lilly: Key highlights
Exhibit 30: Eli Lilly: Strength assessment
Exhibit 31: Eli Lilly: Strategy assessment
Exhibit 32: Eli Lilly: Opportunity assessment
Exhibit 33: F. Hoffman-La Roche: Key highlights
Exhibit 34: F. Hoffman-La Roche: Strength assessment
Exhibit 35: F. Hoffman-La Roche: Strategy assessment
Exhibit 36: F. Hoffman-La Roche: Opportunity assessment
Exhibit 37: Pfizer: Key highlights
Exhibit 38: Pfizer: Strength assessment
Exhibit 39: Pfizer: Strategy assessment
Exhibit 40: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Accord Healthcare
  • AstraZeneca
  • Bedford Lab
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffman-La Roche
  • MORE
New Report Released: - Global Bladder Cancer Therapeutics Market 2017-2021

The author of the report recognizes the following companies as the key players in the global bladder cancer therapeutics market: Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, and Pfizer.

Other Prominent Vendors in the market are: Accord Healthcare, AstraZeneca, Bedford Lab, Merck, and Sanofi.

Commenting on the report, an analyst from the research team said: “One trend in the market is advent of novel pipeline. The global bladder cancer therapeutics market is expected to grow due to the presence of novel therapies in the early stages of the pipeline. For instance, the adoptive cell therapy utilizes the immunotherapy approach for the treatment of bladder cancer.”

According to the report, one driver in the market is growing prevalence rate leads to higher prescription value. Bladder cancer is the ninth-most type of cancer diagnosed worldwide, with the highest incidence rates demonstrated by males in Southern and Western Europe, North America, and in certain countries in Northern Africa or Western Asia. Bladder cancer ranked among 15 most common causes of deaths worldwide.

Further, the report states that one challenge in the market is economic burden of bladder cancer. Bladder cancer accounts one of the highest treatment cost per patient among all other cancers. The high cost of overall treatment is due to a reoccurrence of the tumor, which requires frequent surgical procedures and lifelong surveillance. The data estimates suggest that more than 50,000 incident cases of bladder cancer were reported in the US in 2007.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 6
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffman-La Roche
  • Pfizer
  • Accord Healthcare
  • AstraZeneca
  • Bedford Lab
  • Merck
  • Sanofi
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll